|
|
||||||||
Retrospective Study |
From the Department of Clinical Sciences (Gieger, Rassnick), Cornell University Hospital for Animals, CPC Box 31, Tower Road, Ithaca, New York 14853; New England Veterinary Oncology Group (Siegel), 180 Bear Hill Road, Suite C, Waltham, Massachusetts 02454; Veterinary Teaching Hospital (Proulx), College of Veterinary Medicine, North Carolina State University, 4700 Hillsborough Street, Raleigh, North Carolina 27606; The Animal Medical Center, Donaldson Atwood Cancer Clinic, and Flaherty Comparative Oncology Laboratory (Bergman), 510 East 62nd Street, New York, New York 10021; Angell Memorial Animal Hospital (Anderson), 350 South Huntington Avenue, Boston, Massachusetts 02130; Southeast Veterinary Oncology (LaDue), 280 CorporateWay, Orange Park, Florida 32073; Small Animal Hospital (Smith), College of Veterinary Medicine, Auburn University, Auburn, Alabama 36849; and the Departments of Small Animal Medicine and Surgery (Northrup) and Anatomy and Radiology (Roberts), College of Veterinary Medicine, The University of Georgia, 501 DW Brooks Drive, Athens, Georgia 30602.
Data from 48 dogs with nasal carcinomas treated with palliative radiation therapy (PRT) were retrospectively reviewed. Factors potentially influencing resolution of clinical signs and survival after PRT were evaluated. Clinical signs completely resolved in 66% of dogs for a median of 120 days. The overall median survival time was 146 days. Duration of response to PRT was shorter in dogs that had clinical signs for <90 days before PRT. Survival times were shorter in dogs that had partial or no resolution of clinical signs after PRT than in dogs that had complete resolution of clinical signs.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |